SUBTYPE:Transporter Assays
APPLICATION & SPECIALITY USES:ADME-Toxicology Products and Services

Our OPTI-CNS Panel consists of the major transporters involved in blood-brain barrier pharmacokinetics. The panel can be used to identify and characterize innovative targets for the treatment of neurological diseases, as well as to investigate the efficacy and safety of CNS-related therapeutics.

The panel contains transporters that are found either in the blood-brain barrier, controlling the uptake and efflux of solutes between blood and brain extracellular fluid, or in various regions of the brain and spinal cord, regulating CNS function and neurotransmission. Studies performed with these transporters allow a deeper understanding of the mechanisms involved in neurotransmission, redox signaling and oxidative stress, and energy metabolism.

Our scientific team is composed of thought leaders in CNS transporter research and development. We have been awarded grants by both the FDA and the NIH for correlating therapeutic and adverse effects of drugs and their interactions with a comprehensive panel of CNS transporters. This work allows for a better understanding of the impact of transporters, and therapeutics, on normal brain function and pathology.

Our OPTI-CNS Panel consists of fully characterized transporters known to impact the central nervous system; these transporters are listed below.

In addition to providing CNS-related transporter research services, BioIVT neurological tissues and biospecimens for drug discovery and other research.

TransporterGene NamePredominant CNS endogenous substratesDocumented links to CNS diseases
EAAT1SLC1A3L-Glu, L-AspSchizophrenia, episodic ataxia
EAAT2SLC1A2L-Glu, L-AspNeurodegenerative diseases
EAAT3SLC1A1L-Glu, L-AspObsessive compulsive disorder
CHTSLC5A7CholineAlzheimer's, Parkinson's, dementia
NETSLC6A2Norepinephrine, dopamineADHD, depression
DATSLC6A3DopamineMajor depressive disorder, ADHD, substance abuse
SERTSLC6A4SerotoninMajor depressive disorder, anxiety, panic disorder
GLYT2SLC6A5GlycineHyperekplexia, pain
GAT1SLC6A1GABA, β-alanineEpilepsy, schizophrenia, ADHD
GAT2SLC6A13GABA, β-alanineEpilepsy
GAT3SLC6A11GABA, β-alanineEpilepsy
CRTSLC6A8CreatineCreatine deficiency, mental retardation
PROTSLC6A7ProParkinson's, dystonia
asc-1SLC7A10D-Ser, small neutral amino acidsLearning and memory impairment
CAT3SLC7A3Cationic L-amino acidsAllan-Herndon-Dudley syndrome
xCTSLC7A11Cys (anionic form), L-GluOxidative stress, Parkinson's
OCT2SLC22A2Biogenic aminesMajor depressive disorder, schizophrenia, bipolar disorder
OCT3SLC22A3Biogenic aminesMajor depressive disorder, schizophrenia, bipolar disorder
ENT1SLC29A1AdenosineObsessive compulsive disorder, ischemia
ENT2SLC29A2AdenosineCerebral ischemia
ENT4 (PMAT)SLC29A4Adenosine, biogenic aminesMajor depressive disorder, schizophrenia, bipolar Disorder
SNAT1SLC38A1Gln, Ala, Ser, Cys, His, AsnSuicidal behavior
SNAT2SLC38A2Gln, Ala, Ser, Cys, His, AsnSchizophrenia